Glibenclamide - AMMTeK

Drug Profile

Glibenclamide - AMMTeK

Alternative Names: Amglidia

Latest Information Update: 04 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AMMTeK
  • Developer Assistance Publique Hopitaux de Paris
  • Class Antihyperglycaemics; Benzamides; Small molecules; Sulfonylureas
  • Mechanism of Action KATP channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 2 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus

Most Recent Events

  • 23 Feb 2018 The Committee for Medicinal Products for Human Use (CHMP) recommends granting approval for glibenclamide for Neonatal diabetes in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top